
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Ophthalmol</journal-id><journal-title-group><journal-title>BMC Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">1471-2415</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24766841</article-id><article-id pub-id-type="pmc">4026882</article-id><article-id pub-id-type="publisher-id">1471-2415-14-55</article-id><article-id pub-id-type="doi">10.1186/1471-2415-14-55</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Nakatake</surname><given-names>Shunji</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s-ntake@eye.med.kyushu-u.ac.jp</email></contrib><contrib contrib-type="author" corresp="yes" id="A2"><name><surname>Yoshida</surname><given-names>Shigeo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yosida@med.kyushu-u.ac.jp</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Nakao</surname><given-names>Shintaro</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>snakao@med.kyushu-u.ac.jp</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Arita</surname><given-names>Ryoichi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>r-arita@med.kyushu-u.ac.jp</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Yasuda</surname><given-names>Miho</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>miho-m@info.med.kyushu-u.ac.jp</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Kita</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kita@eye.med.kyushu-u.ac.jp</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Enaida</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>enaida@med.kyushu-u.ac.jp</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Ohshima</surname><given-names>Yuji</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yuji@eye.med.kyushu-u.ac.jp</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Ishibashi</surname><given-names>Tatsuro</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ishi@med.kyushu-u.ac.jp</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>26</day><month>4</month><year>2014</year></pub-date><volume>14</volume><fpage>55</fpage><lpage>55</lpage><history><date date-type="received"><day>25</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Nakatake et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Nakatake et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2415/14/55"/><abstract><sec><title>Background</title><p>Several retinal ischemic diseases can cause neovascular glaucoma (NVG). Trabeculectomy with mitomycin C (MMC) is a relatively better treatment modality in the management of eyes with NVG than other glaucoma surgeries. The aim of this study was to investigate the factors that may influence the outcome of trabeculectomy with MMC for NVG.</p></sec><sec><title>Methods</title><p>Forty-nine NVG eyes from 43 patients (26 males and 17 females) underwent primary trabeculectomy with MMC. The mean follow-up period was 16.8&#x02009;&#x000b1;&#x02009;8.1&#x000a0;months (range, 6 to 34&#x000a0;months). Twenty-one eyes of 21 patients received intravitreal bevacizumab (IVB) 3.6&#x02009;&#x000b1;&#x02009;1.8&#x000a0;days before trabeculectomy with MMC. A Kaplan-Meier survival-curve analysis was used to summarize the cumulative probability of success. We examined the relationship between the surgical outcome and the following surgical factors: gender, age, history of panretinal photocoagulation, history of cataract surgery, history of vitrectomy, preoperative IVB, NVG in the fellow eye, and postoperative complications (hyphema, choroidal detachment, and formation of fibrin) by multivariate analysis.</p></sec><sec><title>Results</title><p>The survival rate was 83.7% after 6&#x000a0;months, 70.9% after 12&#x000a0;months, and 60.8% after 24&#x000a0;months. The Kaplan-Meier survival curves showed no significant difference in the survival rate between the eyes with preoperative IVB (n&#x02009;=&#x02009;21) and the eyes without preoperative IVB (n&#x02009;=&#x02009;28) (p&#x02009;=&#x02009;0.14). The multiple logistic regression analysis showed that postoperative hyphema (odds ratio, 6.54; 95% confidence interval, 1.41 to 35.97) was significantly associated with the surgical outcome (p&#x02009;=&#x02009;0.02).</p></sec><sec><title>Conclusions</title><p>Postoperative hyphema was significantly correlated with the outcome of trabeculectomy for NVG. There was no significant association between preoperative IVB and postoperative hyphema or the results of trabeculectomy.</p></sec></abstract><kwd-group><kwd>Neovascular glaucoma</kwd><kwd>Trabeculectomy</kwd><kwd>Hyphema</kwd><kwd>Mitomycin C</kwd><kwd>Intravitreal bevacizumab</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Several retinal ischemic diseases can cause neovascular glaucoma (NVG): proliferative diabetic retinopathy (PDR), central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), central retinal artery occlusion (CRAO), and ocular ischemic syndrome (OIS) [<xref ref-type="bibr" rid="B1">1</xref>]. Patients with NVG generally present with elevated intraocular pressure (IOP), hyphema, and vitreous hemorrhage. If the elevation in IOP is severe the patient may experience severe pain, and the elevated IOP often results in disastrous visual loss.</p><p>NVG is a severe form of glaucoma characterized by neovascularization and the proliferation of fibrovascular tissue in the anterior chamber angle. In the early open-angle glaucoma stage, anti-glaucoma drugs or panretinal photocoagulation (PRP) may be effective. However, as the disease progresses, the proliferative fibrovascular membrane causes angle closure. This stage is not reversible by PRP and is often refractory to anti-glaucoma drugs. Trabeculectomy with mitomycin C (MMC) is a good treatment modality in the management of eyes with NVG [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>], but its success rate is still poor [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>The pathogenesis of NVG is related to the production of vascular endothelial growth factor (VEGF) by the underlying ischemic retina, which stimulates neovascularization in the anterior chamber angle [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. Bevacizumab is a human monoclonal antibody that binds VEGF and blocks its action. Intravitreal bevacizumab (IVB) was reported to decrease the concentration of VEGF in the aqueous humor [<xref ref-type="bibr" rid="B7">7</xref>], the neovascularization of the anterior chamber, and the IOP to acceptable levels in NVG patients [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. Fluorescein angiography and histochemical investigations demonstrated that there was less vascular permeability and inflammatory reaction in trabecular tissue with IVB than without IVB [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Another histopathological investigation indicated that IVB may induce changes in immature, newly formed vessels, leading to endothelial apoptosis with vascular regression and inducing the normalization of premature vessels in PDR or NVG eyes [<xref ref-type="bibr" rid="B15">15</xref>]. Therefore, IVB before trabeculectomy surgery is expected to have potential as a surgical adjuvant to reduce operative bleeding complications.</p><p>According to previous reports, patient factors such as previous PRP [<xref ref-type="bibr" rid="B16">16</xref>] and history of preoperative IVB [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>] were indicated as good prognostic factors for the surgical outcome of trabeculectomy for NVG, whereas a history of vitrectomy [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B18">18</xref>], and younger age [<xref ref-type="bibr" rid="B18">18</xref>] were indicated as adverse prognostic factors. However, it is not yet known which factors are definite prognostic factors [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. In addition, to the best of our knowledge there has been no report about the effect of early postoperative hyphema on the success rate of trabeculectomy with NVG. In the present study, we investigated the surgical prognostic factors of trabeculectomy.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>We retrospectively reviewed the medical records of 49 NVG eyes from 43 patients (26 males and 17 females) with the presence of neovascularization in the anterior chamber angle and uncontrolled IOP. All patients underwent primary trabeculectomy with MMC at Kyushu University Hospital, Japan, between January 2008 and July 2010 and could be followed up for more than 6&#x000a0;months. This study was approved by the Ethics Committee of Kyushu University (Ethics Approval Number: 19002). No patients underwent any other glaucoma surgery before the primary trabeculectomy. The etiology of NVG was PDR (43 eyes), CRVO (2 eyes), and CRAO, BRVO, OIS and uveitis (1 eye each). PRP was performed as much as possible except for patients who could not undergo PRP because of vitreous hemorrhage or corneal edema. Excluding those with a history of ischemic cardiac disease or brain infarction and in poor general status, 21 eyes of 21 patients received IVB (1.25&#x000a0;mg/0.05&#x000a0;mL) at 1 to 7 (3.6&#x02009;&#x000b1;&#x02009;1.8) days before trabeculectomy with MMC after 2009 March.</p></sec><sec><title>Surgical technique</title><p>All 43 patients underwent trabeculectomy with MMC. A fornix-based conjunctival flap was made. After hemostasis of the episcleral blood vessels with wet-fluid cautery, a 3&#x02009;&#x000d7;&#x02009;3-mm, half-thickness triangle scleral flap was made. Surgical sponges soaked in MMC (0.4&#x000a0;mg/mL) were placed under the conjunctival flap for 3&#x000a0;min, followed by irrigation with 300&#x000a0;mL of physiologic saline. A deep trabecular block was removed and a peripheral iridectomy was performed. The scleral flap was sutured with 10-0 nylon sutures. All patients received topical treatment including 0.5% levofloxacin and 0.1% betamethasone for 1 to 3&#x000a0;months after the operation, and the patients whose IOP was elevated received anti-glaucoma drugs. Postoperatively, argon laser suture lysis was performed, depending on the level of IOP and the condition of the conjunctival bleb formation.</p></sec><sec><title>Data analysis</title><p>The criteria for successful surgery were: IOP&#x02009;&#x0003c;&#x02009;20&#x000a0;mmHg with or without anti-glaucoma drugs, visual acuity more than light perception, and no additional glaucoma surgery (shunt insertion or cyclophotocoagulation). The following patient data were collected: age, gender, preoperative and postoperative (1&#x000a0;week, 1, 2, 3, and 6&#x000a0;months after the surgery, and last visit) IOP, lens status, previous surgical ocular history (except for glaucoma surgery), preoperative and postoperative visual acuity, the number of preoperative and postoperative anti-glaucoma drugs the patient had been taking, and postoperative complications.</p><p>Hyphema, one of the potential postoperative complications of trabeculectomy, was defined as hemorrhage in the anterior chamber to the extent of making niveau, even if only a little. Eyes that showed only suspended red blood cells in the anterior chamber, without making niveau, were not defined as having hyphema. The patients&#x02019; visual acuity was measured by assessing their decimal visual acuity, and it was calculated after conversion to the logarithm of the minimum of resolution (logMAR).</p><p>A Kaplan-Meier survival curve was used to estimate the probability of the success rate. We examined the relationships between the surgical risk factors and the surgical outcome. We considered the following ten possible risk factors for surgical outcome: gender, age, history of previous PRP, history of cataract surgery, history of vitrectomy, concurrent vitrectomy, preoperative IVB, NVG in the fellow eye, postoperative hyphema, postoperative choroidal detachment, and postoperative formation of fibrin. All variables were treated as categorical variables. Each categorical variable was coded as either 1 or 0 depending on the presence or absence of the factor, respectively. Frequencies were compared by chi-square test.</p><p>We estimated the multivariate odds ratio (OR) and 95% confidence interval (CI) of the following three potential risk factors by using a logistic regression analysis: history of vitrectomy [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B18">18</xref>], preoperative IVB [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>], both of which have been reported to affect the surgical outcome, and postoperative hyphema. The JMP version 9 statistical package program (Cary, NC) was used to perform the statistical analyses. A two-sided p-value of less than 0.05 was considered significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Table&#x000a0;<xref ref-type="table" rid="T1">1</xref> shows the baseline characteristics of all 49 eyes. The mean age of the patients was 55.6&#x02009;&#x000b1;&#x02009;11.5&#x000a0;years with a range from 30 to 79&#x000a0;years. Twelve patients (14 eyes) were less than 50&#x000a0;years old, and 31 patients (35 eyes) were&#x02009;&#x02265;&#x02009;50&#x000a0;years old. The mean follow-up period was 16.8&#x02009;&#x000b1;&#x02009;8.1&#x000a0;months with a range from 6 to 34&#x000a0;months. All eyes were followed up for 6&#x000a0;months or more; 34 eyes were followed for 12&#x000a0;months or more, and 12 eyes were followed for 24&#x000a0;months or more. The mean preoperative IOP was 30.4&#x02009;&#x000b1;&#x02009;13.1&#x000a0;mmHg, and the mean last-visit IOP was 16.0&#x02009;&#x000b1;&#x02009;9.9&#x000a0;mmHg. Forty-two eyes received PRP. The other 7 eyes could not undergo sufficient retinal photocoagulation because of vitreous hemorrhage or corneal edema. Twenty-one eyes underwent preoperative IVB at 3.6&#x02009;&#x000b1;&#x02009;1.8 (range 1&#x02013;7) days before trabeculectomy.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics of 43 patients (49 eyes) who underwent trabeculectomy with MMC for NVG</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Characteristic</bold></th><th align="left"><bold>Value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Gender<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Male<hr/></td><td align="left" valign="bottom">26 (60.5%)<hr/></td></tr><tr><td align="left" valign="bottom">Female<hr/></td><td align="left" valign="bottom">17 (39.5%)<hr/></td></tr><tr><td align="left" valign="bottom">Age (years)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Mean&#x02009;&#x000b1;&#x02009;SD<hr/></td><td align="left" valign="bottom">55.6&#x02009;&#x000b1;&#x02009;11.5<hr/></td></tr><tr><td align="left" valign="bottom">Range<hr/></td><td align="left" valign="bottom">30&#x02013;79<hr/></td></tr><tr><td align="left" valign="bottom">Follow-up (months)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Mean&#x02009;&#x000b1;&#x02009;SD<hr/></td><td align="left" valign="bottom">16.8&#x02009;&#x000b1;&#x02009;8.1<hr/></td></tr><tr><td align="left" valign="bottom">Range<hr/></td><td align="left" valign="bottom">6&#x02013;34<hr/></td></tr><tr><td align="left" valign="bottom">Preoperative IOP (mmHg)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Mean&#x02009;&#x000b1;&#x02009;SD<hr/></td><td align="left" valign="bottom">30.4&#x02009;&#x000b1;&#x02009;13.1<hr/></td></tr><tr><td align="left" valign="bottom">Range<hr/></td><td align="left" valign="bottom">7&#x02013;60<hr/></td></tr><tr><td align="left" valign="bottom">Prior surgery<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Cataract<hr/></td><td align="left" valign="bottom">39 (79.6%)<hr/></td></tr><tr><td align="left" valign="bottom">Pseudophakia<hr/></td><td align="left" valign="bottom">37 (75.5%)<hr/></td></tr><tr><td align="left" valign="bottom">Aphakia<hr/></td><td align="left" valign="bottom">2 (4.1%)<hr/></td></tr><tr><td align="left" valign="bottom">Vitrectomy<hr/></td><td align="left" valign="bottom">30 (61.2%)<hr/></td></tr><tr><td align="left" valign="bottom">20-gauge system<hr/></td><td align="left" valign="bottom">28 (57.1%)<hr/></td></tr><tr><td align="left" valign="bottom">23-gauge system<hr/></td><td align="left" valign="bottom">2 (4.1%)<hr/></td></tr><tr><td align="left" valign="bottom">Concurrent vitrectomy<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Yes<hr/></td><td align="left" valign="bottom">25 (51.0%)<hr/></td></tr><tr><td align="left" valign="bottom">No<hr/></td><td align="left" valign="bottom">24 (49.0%)<hr/></td></tr><tr><td align="left" valign="bottom">NVG in fellow eye<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Yes<hr/></td><td align="left" valign="bottom">13 (26.6%)<hr/></td></tr><tr><td align="left" valign="bottom">No<hr/></td><td align="left" valign="bottom">36 (73.4%)<hr/></td></tr><tr><td align="left" valign="bottom">Anti-glaucoma drugs<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Preoperative (mean&#x02009;&#x000b1;&#x02009;SD)<hr/></td><td align="left" valign="bottom">2.4&#x02009;&#x000b1;&#x02009;0.9<hr/></td></tr><tr><td align="left" valign="bottom">Postoperative (mean&#x02009;&#x000b1;&#x02009;SD)<hr/></td><td align="left" valign="bottom">1.4&#x02009;&#x000b1;&#x02009;1.3<hr/></td></tr><tr><td align="left" valign="bottom">Previous PRP<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Yes<hr/></td><td align="left" valign="bottom">42 (85.7%)<hr/></td></tr><tr><td align="left" valign="bottom">No<hr/></td><td align="left" valign="bottom">7 (14.3%)<hr/></td></tr><tr><td align="left" valign="bottom">Preoperative IVB<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Yes<hr/></td><td align="left" valign="bottom">21 (42.9%)<hr/></td></tr><tr><td align="left">No</td><td align="left">28 (57.1%)</td></tr></tbody></table><table-wrap-foot><p>MMC: mitomycin C.</p></table-wrap-foot></table-wrap><p>Table&#x000a0;<xref ref-type="table" rid="T2">2</xref> shows the postoperative complications of trabeculectomy with MMC in patients with NVG. Eleven eyes developed hyphema: 9 eyes at postoperative 1&#x000a0;day, 1 eye at postoperative 2&#x000a0;days, and 1 eye at postoperative 4&#x000a0;days. Four eyes had developed a formation of fibrin in the anterior chamber, and 5 eyes had developed choroidal detachment as postoperative surgical complications. Of all 49 eyes, 35 eyes were successes, and 14 eyes were failures.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Postoperative complications</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th rowspan="2" align="left"><bold>Disease</bold></th><th align="left" valign="bottom"><bold>Eyes (%)</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>Eyes</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left"><bold>IVB</bold></th><th align="left"><bold>not IVB</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Hyphema<hr/></td><td align="left" valign="bottom">11 (22.4%)<hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">5<hr/></td></tr><tr><td align="left" valign="bottom">Formation of fibrin<hr/></td><td align="left" valign="bottom">4 (8.2%)<hr/></td><td align="left" valign="bottom">0<hr/></td><td align="left" valign="bottom">4<hr/></td></tr><tr><td align="left">Choroidal detachment</td><td align="left">5 (10.2%)</td><td align="left">1</td><td align="left">4</td></tr></tbody></table></table-wrap><p>Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref> is the Kaplan-Meier survival curve of all eyes. All 49 eyes were evaluated after 6&#x000a0;months, 34 eyes were evaluated after 12&#x000a0;months, and 12 eyes were evaluated after 24&#x000a0;months. The survival rate was 83.7% after 6&#x000a0;months, 70.9% after 12&#x000a0;months, and 60.8% after 24&#x000a0;months. Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref> is the Kaplan-Meier survival curve for the two groups (IVB group vs. not-IVB group). Until 23&#x000a0;months after the trabeculectomy, the survival rate of the IVB group was higher than that of the not-IVB group, but there was no significant difference between the two groups (p&#x02009;=&#x02009;0.41).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Kaplan-Meier survival curve of all eyes.</bold> The survival rate was 83.7% after 6&#x000a0;months, 70.9% after 12&#x000a0;months, and 60.8% after 24&#x000a0;months.</p></caption><graphic xlink:href="1471-2415-14-55-1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Kaplan-Meier survival curve for IVB group vs. not-IVB group.</bold> Kaplan-Meier survival curve of the surgical outcomes of trabeculectomies with MMC in eyes with IVB (n&#x02009;=&#x02009;21, continuous line) and eyes without IVB (n&#x02009;=&#x02009;28, dotted line). There was no significant difference between the two groups (p&#x02009;=&#x02009;0.41).</p></caption><graphic xlink:href="1471-2415-14-55-2"/></fig><p>Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref> is the Kaplan-Meier survival curve of the surgical outcomes of the trabeculectomies with MMC in eyes with and without hyphema. The survival rate of the group without hyphema was significantly higher than the group with hyphema (p&#x02009;&#x0003c;&#x02009;0.01). Table&#x000a0;<xref ref-type="table" rid="T3">3</xref> shows the frequencies of the surgical risk factors that potentially influence the results of trabeculectomy for NVG. The frequency of postoperative hyphema was significantly higher in the failure group than in the success group. Table&#x000a0;<xref ref-type="table" rid="T4">4</xref> shows the results of the multivariate analysis for the factors that influenced the surgical outcome. In the multivariate analysis, postoperative hyphema was significantly associated with the surgical outcome (p&#x02009;&#x0003c;&#x02009;0.02).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Kaplan-Meier survival curve for the groups with hyphema vs. without hyphema.</bold> Kaplan-Meier survival curve of the surgical outcomes of trabeculectomies with MMC in eyes with hyphema (n&#x02009;=&#x02009;11, continuous line) and eyes without hyphema (n&#x02009;=&#x02009;38, dotted line). There was a significant difference between the two groups (p&#x02009;&#x0003c;&#x02009;0.01).</p></caption><graphic xlink:href="1471-2415-14-55-3"/></fig><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Frequencies of surgical risk factors that influence the result of trabeculectomy with MMC for NVG</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variable:</bold></th><th align="left"><bold>Success group (35 eyes) Number of eyes (Percentage of eyes)</bold></th><th align="left"><bold>Failure group (14 eyes) Number of eyes (Percentage of eyes)</bold></th><th align="left"><bold>p-value (Chi-square test)</bold></th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="bottom">Gender (Male)<hr/></td><td align="left" valign="bottom">20<hr/></td><td align="left" valign="bottom">9<hr/></td><td rowspan="2" align="left" valign="bottom">0.65<hr/></td></tr><tr><td align="left" valign="bottom">(57.1%)<hr/></td><td align="left" valign="bottom">(64.3%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">Age (50&#x0003c;)<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">5<hr/></td><td rowspan="2" align="left" valign="bottom">0.49<hr/></td></tr><tr><td align="left" valign="bottom">(25.7%)<hr/></td><td align="left" valign="bottom">(35.7%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">History of previous PRP<hr/></td><td align="left" valign="bottom">30<hr/></td><td align="left" valign="bottom">12<hr/></td><td rowspan="2" align="left" valign="bottom">1.00<hr/></td></tr><tr><td align="left" valign="bottom">(85.7%)<hr/></td><td align="left" valign="bottom">(85.7%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">History of cataract surgery<hr/></td><td align="left" valign="bottom">29<hr/></td><td align="left" valign="bottom">10<hr/></td><td rowspan="2" align="left" valign="bottom">0.37<hr/></td></tr><tr><td align="left" valign="bottom">(82.9%)<hr/></td><td align="left" valign="bottom">(71.4%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">History of vitrectomy<hr/></td><td align="left" valign="bottom">23<hr/></td><td align="left" valign="bottom">7<hr/></td><td rowspan="2" align="left" valign="bottom">0.31<hr/></td></tr><tr><td align="left" valign="bottom">(65.7%)<hr/></td><td align="left" valign="bottom">(50.0%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">Concurrent vitrectomy<hr/></td><td align="left" valign="bottom">18<hr/></td><td align="left" valign="bottom">7<hr/></td><td rowspan="2" align="left" valign="bottom">0.93<hr/></td></tr><tr><td align="left" valign="bottom">(51.4%)<hr/></td><td align="left" valign="bottom">(50.0%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">Preoperative IVB<hr/></td><td align="left" valign="bottom">16<hr/></td><td align="left" valign="bottom">5<hr/></td><td rowspan="2" align="left" valign="bottom">0.52<hr/></td></tr><tr><td align="left" valign="bottom">(45.7%)<hr/></td><td align="left" valign="bottom">(35.7%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">NVG in the fellow eye<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">4<hr/></td><td rowspan="2" align="left" valign="bottom">0.84<hr/></td></tr><tr><td align="left" valign="bottom">(25.7%)<hr/></td><td align="left" valign="bottom">(28.6%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">Postoperative hyphema<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">6<hr/></td><td rowspan="2" align="left" valign="bottom">0.03<hr/></td></tr><tr><td align="left" valign="bottom">(14.3%)<hr/></td><td align="left" valign="bottom">(42.9%)<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">Postoperative choroidal detachment<hr/></td><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">1<hr/></td><td rowspan="2" align="left" valign="bottom">0.65<hr/></td></tr><tr><td align="left" valign="bottom">(11.4%)<hr/></td><td align="left" valign="bottom">(7.1%)<hr/></td></tr><tr><td rowspan="2" align="left">Postoperative formation of fibrin</td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">2<hr/></td><td rowspan="2" align="left">0.32</td></tr><tr><td align="left">(5.7%)</td><td align="left">(14.3%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Multivariate analysis of the factors that influence the result of trabeculectomy with MMC for NVG</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variable</bold></th><th align="left"><bold>Odds ratio</bold></th><th align="left"><bold>95% CI</bold></th><th align="left"><bold>p-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">History of vitrectomy<hr/></td><td align="left" valign="bottom">0.26<hr/></td><td align="left" valign="bottom">0.05&#x02013;1.21<hr/></td><td align="left" valign="bottom">0.09<hr/></td></tr><tr><td align="left" valign="bottom">Preoperative IVB<hr/></td><td align="left" valign="bottom">0.28<hr/></td><td align="left" valign="bottom">0.05&#x02013;1.30<hr/></td><td align="left" valign="bottom">0.10<hr/></td></tr><tr><td align="left">Postoperative hyphema</td><td align="left">6.54</td><td align="left">1.41&#x02013;35.97</td><td align="left">0.02</td></tr></tbody></table><table-wrap-foot><p>CI, confidence interval.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>Even with some therapies, the IOP is often increased to an uncontrolled level, sometimes leading to blindness. According to a systematic review and meta-analysis of comparative studies of two or more surgical techniques (one of which had to be trabeculectomy), including patients with open-angle glaucoma, trabeculectomy still offers the possibility of obtaining excellent IOP control at the long-term follow-up in patients with open-angle glaucoma [<xref ref-type="bibr" rid="B19">19</xref>], whereas the success rate of trabeculectomy for NVG is still poor [<xref ref-type="bibr" rid="B5">5</xref>]. In the present study, the survival rate of trabeculectomy for NVG was 83.7% after 6&#x000a0;months, 70.9% after 12&#x000a0;months, and 60.8% after 24&#x000a0;months.</p><p>Several previous studies investigated the success rate of trabeculectomy with MMC for NVG. One study reported that the cumulative probability of the success of trabeculectomy was 67.0% after 1&#x000a0;year and 61.8% after 2 to 3&#x000a0;years [<xref ref-type="bibr" rid="B3">3</xref>]. According to another report, the probability of success at 120, 240 and 360&#x000a0;days after combined preoperative IVB and trabeculectomy was 87.5%, 79.2%, and 65.2%, respectively, but the corresponding values after only trabeculectomy without IVB were 75.0%, 71.9%, and 65.3%, respectively [<xref ref-type="bibr" rid="B20">20</xref>]. Our surgical outcomes in the present study are similar to these reports.</p><p>Although there was a trend for less failure in the IVB group until postoperative 23&#x000a0;months, preoperative IVB finally did not significantly improve the outcome of trabeculectomy with MMC for NVG in our study. Moreover, it did not decrease the risk of postoperative hyphema. Sugimoto et al. [<xref ref-type="bibr" rid="B21">21</xref>], using resected irises from NVG patients during trabeculectomy, reported that IVB reduced the neovascularization on the iris surface but could not completely eliminate neovascularization in the iris stroma. They also reported that IVB did not prevent postoperative complications at 1&#x000a0;day after trabeculectomy, including hyphema [<xref ref-type="bibr" rid="B21">21</xref>]. Takihara et al., performing IVB 1 to 5&#x000a0;days before the trabeculectomy for NVG patients, reported that preoperative IVB did not significantly improve the surgical outcomes, in common with our study [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>In contrast, Saito et al. reported that preoperative IVB decreased postoperative hyphema and increased the surgical success rate [<xref ref-type="bibr" rid="B17">17</xref>]. The discrepancy between these studies may be due to the different intervals between the IVB and the trabeculectomy: in the Sugimoto study and Takihara study, they performed the IVB 6 to 8&#x000a0;days and 1 to 5&#x000a0;days before the trabeculectomy, respectively, whereas in the Saito study, the IVB was performed 10&#x02009;&#x000b1;&#x02009;11&#x000a0;days before the trabeculectomy. In our study, the IVB was performed 3.6&#x02009;&#x000b1;&#x02009;1.8&#x000a0;days before the trabeculectomy, and the results are consistent with the Sugimoto study and Takihara study. Considering these data, using a sufficiently long interval between the IVB and trabeculectomy may be more effective by calming down the activity of neovascularization in the anterior segment.</p><p>Another study demonstrated that NVG eyes with a history of vitrectomy had poor surgical outcomes after trabeculectomy [<xref ref-type="bibr" rid="B22">22</xref>]. Vitrectomy exacerbates retinal ischemia and increases the concentration of inflammatory cytokines and/or VEGF in the anterior chamber [<xref ref-type="bibr" rid="B3">3</xref>]. Our present analysis did not find that previous vitrectomy is a prognostic factor. Thirty eyes had already undergone a vitrectomy before trabeculectomy, and 25 eyes underwent a vitrectomy concurrently to receive more photocoagulation to the extreme periphery of the retina intraoperatively. Additional photocoagulation may improve retinal ischemia; here it may have led to the satisfactory surgical outcomes. Moreover, some reports indicated that younger NVG patients have a poor success rate following trabeculectomy [<xref ref-type="bibr" rid="B18">18</xref>], but in the present study we found no significant difference in the surgical outcome between patients under 50&#x000a0;years old (14 eyes) and those&#x02009;&#x02265;&#x02009;50&#x000a0;years old (35 eyes). This may be because there were many more patients over 50&#x000a0;years old in our study.</p><p>Trabeculectomy in NVG patients usually results in frequent postoperative complications and poor surgical outcomes. Hyphema has been described as the most frequent postoperative complication of trabeculectomy in NVG patients [<xref ref-type="bibr" rid="B16">16</xref>]. However, there is no report that postoperative hyphema significantly influences the surgical outcome of trabeculectomy with NVG. In the present study, hyphema was the most common postoperative complication, and we also found that postoperative hyphema was a significant prognostic factor in trabeculectomy for NVG. Moreover, patients with PDR were found in another study to have significantly higher serum levels of cytokines such as interleukin (IL)-6, tumor necrosis factor-alpha (TNF-&#x003b1; and VEGF compared to non-PDR patients [<xref ref-type="bibr" rid="B23">23</xref>]. The serum levels of TNF-&#x003b1;, IL-6, and C-reactive protein (CRP) were also higher in subjects with arteriosclerotic peripheral vascular disease compared to healthy controls [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>TNF and IL-1 were reported to be capable of stimulating the proliferation of Tenon&#x02019;s capsule fibroblasts [<xref ref-type="bibr" rid="B25">25</xref>]. Moreover, Cvenkel et al. indicated that lower levels of TNF-&#x003b1; and IL-6 in the aqueous humor were associated with better surgical outcomes in patients undergoing trabeculectomy [<xref ref-type="bibr" rid="B26">26</xref>]. Tripathi et al. reported the results of an intracameral injection of tissue plasminogen activator in the anterior chamber for eyes with fibrin clots and elevated IOP after glaucoma filtering procedures [<xref ref-type="bibr" rid="B27">27</xref>]; soon after the injection, the fibrin clots dissolved completely and the elevated IOP values decreased to the normal level. Tripathi et al. suggested that fibrin clots after filtering surgery provide a scaffold for the formation of scar tissue in the anterior chamber and in the fistulization tract.</p><p>In view of these reports, when hyphema occurs after trabeculectomy, increased concentrations of some cytokines may lead to a failure of conjunctival bleb formation. Additionally, blood flow into the trabecular meshwork may lead to a stronger wound-healing response or clog the flow of aqueous humor, but further study is required to test this notion.</p><p>There are a few reports about reducing the incidence of hyphema following trabeculectomy. Wilson et al. reported that during trabeculectomy, filling the anterior chamber with sodium hyaluronate reduced the incidence of postoperative hyphema for glaucoma patients with primary open-angle glaucoma, chronic angle closure glaucoma, congenital glaucoma, or NVG [<xref ref-type="bibr" rid="B28">28</xref>]; they suggested that the reduced incidence was due to a microvascular clotting effect or the tamponade of higher intraocular pressure. To avoid unfavorable hyphema, Elgin et al. used direct cauterization of the iris before iridectomy, and they reported that this protocol effectively reduced the rate of intraoperative bleeding and postoperative hyphema in trabeculectomy for NVG [<xref ref-type="bibr" rid="B29">29</xref>]. The direct cauterization of the iris seeking to reduce postoperative bleeding may be a beneficial new procedure for better prognosis in NVG patients.</p><p>In addition, as a new glaucoma surgery, the Ex-PRESS drainage device was introduced in 2011 as an alternative to trabeculectomy [<xref ref-type="bibr" rid="B30">30</xref>]. During this operation, iridectomy is not required, and thus hyphema is less likely compared to the use of trabeculectomy. The results of our present retrospective study indicate that postoperative hyphema could be a surgical risk factor for failure of trabeculectomy in NVG, but in light of the study&#x02019;s retrospective nature, further prospective randomized investigations are required. Filling the anterior chamber with ophthalmic viscosurgical devices intraoperatively, the direct cauterization of the iris, or the use of the Ex-PRESS drainage device may provide better prognoses in NVG patients.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In the present study, we found that postoperative hyphema was a significant prognostic factor in trabeculectomy for NVG. There was no clear association between preoperative IVB and postoperative hyphema or the result of trabeculectomy.</p></sec><sec><title>Abbreviations</title><p>NVG: Neovascular glaucoma; MMC: Mitomycin C; IVB: Intravitreal bevacizumab; PDR: Proliferative diabetic retinopathy; CRVO: Central retinal vein occlusion; BRVO: Branch retinal vein occlusion; CRAO: Central retinal artery occlusion; OIS: Ocular ischemic syndrome; IOP: Intraocular pressure; PRP: Panretinal photocoagulation; VEGF: Vascular endothelial growth factor; OR: Odds ratio; CI: Confidence interval.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>SN participated in the design of the study, performed the statistical analysis and drafted the manuscript. SY is the main researcher and the corresponding author. SN and RA recorded the data of the patients. MY participated in collecting the data and in the statistical analyses. TK, HE and YO drafted and revised the manuscript. TI participated in the design and final approval of manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2415/14/55/prepub">http://www.biomedcentral.com/1471-2415/14/55/prepub</ext-link></p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Avery</surname><given-names>RL</given-names></name><name><surname>Arrigg</surname><given-names>PG</given-names></name><name><surname>Keyt</surname><given-names>BA</given-names></name><name><surname>Jampel</surname><given-names>HD</given-names></name><name><surname>Shah</surname><given-names>ST</given-names></name><name><surname>Pasquale</surname><given-names>LR</given-names></name><name><surname>Thieme</surname><given-names>H</given-names></name><name><surname>Iwamoto</surname><given-names>MA</given-names></name><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Nguyen</surname><given-names>HV</given-names></name><name><surname>Aiello</surname><given-names>LM</given-names></name><name><surname>Napoleone</surname><given-names>F</given-names></name><name><surname>King</surname><given-names>GL</given-names></name><article-title>Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><fpage>1480</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1056/NEJM199412013312203</pub-id><pub-id pub-id-type="pmid">7526212</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Mandal</surname><given-names>AK</given-names></name><name><surname>Majji</surname><given-names>AB</given-names></name><name><surname>Mandal</surname><given-names>SP</given-names></name><name><surname>Das</surname><given-names>T</given-names></name><name><surname>Jalali</surname><given-names>S</given-names></name><name><surname>Gothwal</surname><given-names>VK</given-names></name><name><surname>Jain</surname><given-names>SS</given-names></name><name><surname>Nutheti</surname><given-names>R</given-names></name><article-title>Mitomycin-C-augmented trabeculectomy for neovascular glaucoma. A preliminary report</article-title><source>Indian J Ophthalmol</source><year>2002</year><volume>50</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">12532493</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Kiuchi</surname><given-names>Y</given-names></name><name><surname>Sugimoto</surname><given-names>R</given-names></name><name><surname>Nakae</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><article-title>Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients</article-title><source>Ophthalmologica</source><year>2006</year><volume>220</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1159/000095865</pub-id><pub-id pub-id-type="pmid">17095884</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Hyung</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><article-title>Mid-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients</article-title><source>Korean J Ophthalmol</source><year>2001</year><volume>15</volume><fpage>98</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">11811590</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Sivak-Callcott</surname><given-names>JA</given-names></name><name><surname>O'Day</surname><given-names>DM</given-names></name><name><surname>Gass</surname><given-names>JD</given-names></name><name><surname>Tsai</surname><given-names>JC</given-names></name><article-title>Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>1767</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(01)00775-8</pub-id><pub-id pub-id-type="pmid">11581047</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Tripathi</surname><given-names>RC</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Tripathi</surname><given-names>BJ</given-names></name><name><surname>Chalam</surname><given-names>KV</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name><article-title>Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>232</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/S0161-6420(98)92782-8</pub-id><pub-id pub-id-type="pmid">9479280</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>TH</given-names></name><name><surname>Bae</surname><given-names>SH</given-names></name><name><surname>Cho</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Sohn</surname><given-names>YH</given-names></name><article-title>Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma</article-title><source>Korean J Ophthalmol</source><year>2009</year><volume>23</volume><fpage>188</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.3341/kjo.2009.23.3.188</pub-id><pub-id pub-id-type="pmid">19794946</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Wakabayashi</surname><given-names>T</given-names></name><name><surname>Oshima</surname><given-names>Y</given-names></name><name><surname>Sakaguchi</surname><given-names>H</given-names></name><name><surname>Ikuno</surname><given-names>Y</given-names></name><name><surname>Miki</surname><given-names>A</given-names></name><name><surname>Gomi</surname><given-names>F</given-names></name><name><surname>Otori</surname><given-names>Y</given-names></name><name><surname>Kamei</surname><given-names>M</given-names></name><name><surname>Kusaka</surname><given-names>S</given-names></name><name><surname>Tano</surname><given-names>Y</given-names></name><article-title>Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases</article-title><source>Ophthalmology</source><year>2008</year><volume>115</volume><fpage>1571</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2008.02.026</pub-id><pub-id pub-id-type="pmid">18440643</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>R</given-names></name><name><surname>Harada</surname><given-names>Y</given-names></name><name><surname>Tou</surname><given-names>N</given-names></name><name><surname>Tawara</surname><given-names>A</given-names></name><article-title>Intravitreal injection of bevacizumab to treat neovascular glaucoma</article-title><source>Jpn J Ophthalmol</source><year>2008</year><volume>52</volume><fpage>410</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1007/s10384-008-0573-3</pub-id><pub-id pub-id-type="pmid">18991046</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Von Jagow</surname><given-names>B</given-names></name><name><surname>Ulbig</surname><given-names>M</given-names></name><name><surname>Haritoglou</surname><given-names>C</given-names></name><article-title>Intracameral injection of bevacizumab for the treatment of neovascular glaucoma</article-title><source>Ophthalmologica</source><year>2008</year><volume>226</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">21546781</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Vasudev</surname><given-names>D</given-names></name><name><surname>Blair</surname><given-names>MP</given-names></name><name><surname>Galasso</surname><given-names>J</given-names></name><name><surname>Kapur</surname><given-names>R</given-names></name><name><surname>Vajaranant</surname><given-names>T</given-names></name><article-title>Intravitreal bevacizumab for neovascular glaucoma</article-title><source>J Ocul Pharmacol Ther</source><year>2009</year><volume>25</volume><fpage>453</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1089/jop.2009.0036</pub-id><pub-id pub-id-type="pmid">19857107</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Beutel</surname><given-names>J</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Luke</surname><given-names>M</given-names></name><name><surname>Aisenbrey</surname><given-names>S</given-names></name><name><surname>Szurman</surname><given-names>P</given-names></name><name><surname>Spitzer</surname><given-names>MS</given-names></name><name><surname>Yoeruek</surname><given-names>E</given-names></name><name><surname>Grisanti</surname><given-names>S</given-names></name><article-title>Bevacizumab as adjuvant for neovascular glaucoma</article-title><source>Acta Ophthalmol</source><year>2010</year><volume>88</volume><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/j.1755-3768.2008.01355.x</pub-id><pub-id pub-id-type="pmid">18811641</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Ishibashi</surname><given-names>S</given-names></name><name><surname>Tawara</surname><given-names>A</given-names></name><name><surname>Sohma</surname><given-names>R</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Toh</surname><given-names>N</given-names></name><article-title>Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection</article-title><source>Arch Ophthalmol</source><year>2010</year><volume>128</volume><fpage>1539</fpage><lpage>1545</lpage><pub-id pub-id-type="doi">10.1001/archophthalmol.2010.282</pub-id><pub-id pub-id-type="pmid">21149776</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Hisatomi</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Kohno</surname><given-names>R</given-names></name><name><surname>Murakami</surname><given-names>Y</given-names></name><name><surname>Imaki</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>A</given-names></name><name><surname>Fujisawa</surname><given-names>K</given-names></name><name><surname>Ishibashi</surname><given-names>T</given-names></name><article-title>Intravitreal bevacizumab treatment for neovascular glaucoma: histopathological analysis of trabeculectomy specimens</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2011</year><volume>249</volume><fpage>1547</fpage><lpage>1552</lpage><pub-id pub-id-type="doi">10.1007/s00417-011-1761-2</pub-id><pub-id pub-id-type="pmid">21842129</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Kohno</surname><given-names>R</given-names></name><name><surname>Hata</surname><given-names>Y</given-names></name><name><surname>Mochizuki</surname><given-names>Y</given-names></name><name><surname>Arita</surname><given-names>R</given-names></name><name><surname>Kawahara</surname><given-names>S</given-names></name><name><surname>Kita</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Hisatomi</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Ishibashi</surname><given-names>T</given-names></name><article-title>Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection</article-title><source>Am J Ophthalmol</source><year>2010</year><volume>150</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2010.03.016</pub-id><pub-id pub-id-type="pmid">20542485</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Alkawas</surname><given-names>AA</given-names></name><name><surname>Shahien</surname><given-names>EA</given-names></name><name><surname>Hussein</surname><given-names>AM</given-names></name><article-title>Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C</article-title><source>J Glaucoma</source><year>2010</year><volume>19</volume><fpage>622</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1097/IJG.0b013e3181ccb794</pub-id><pub-id pub-id-type="pmid">20179624</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Higashide</surname><given-names>T</given-names></name><name><surname>Takeda</surname><given-names>H</given-names></name><name><surname>Ohkubo</surname><given-names>S</given-names></name><name><surname>Sugiyama</surname><given-names>K</given-names></name><article-title>Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma</article-title><source>Acta Ophthalmol</source><year>2010</year><volume>88</volume><fpage>96</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/j.1755-3768.2009.01648.x</pub-id><pub-id pub-id-type="pmid">19775309</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Takihara</surname><given-names>Y</given-names></name><name><surname>Inatani</surname><given-names>M</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Iwao</surname><given-names>K</given-names></name><name><surname>Iwao</surname><given-names>M</given-names></name><name><surname>Tanihara</surname><given-names>H</given-names></name><article-title>Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure</article-title><source>Am J Ophthalmol</source><year>2009</year><volume>147</volume><fpage>912</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2008.11.015</pub-id><pub-id pub-id-type="pmid">19195639</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Rulli</surname><given-names>E</given-names></name><name><surname>Biagioli</surname><given-names>E</given-names></name><name><surname>Riva</surname><given-names>I</given-names></name><name><surname>Gambirasio</surname><given-names>G</given-names></name><name><surname>De Simone</surname><given-names>I</given-names></name><name><surname>Floriani</surname><given-names>I</given-names></name><name><surname>Quaranta</surname><given-names>L</given-names></name><article-title>Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis</article-title><source>JAMA Ophthalmol</source><year>2013</year><volume>131</volume><fpage>1573</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2013.5059</pub-id><pub-id pub-id-type="pmid">24158640</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Takihara</surname><given-names>Y</given-names></name><name><surname>Inatani</surname><given-names>M</given-names></name><name><surname>Kawaji</surname><given-names>T</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Iwao</surname><given-names>K</given-names></name><name><surname>Iwao</surname><given-names>M</given-names></name><name><surname>Tanihara</surname><given-names>H</given-names></name><article-title>Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma</article-title><source>J Glaucoma</source><year>2011</year><volume>20</volume><fpage>196</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1097/IJG.0b013e3181d9ce12</pub-id><pub-id pub-id-type="pmid">20440215</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Sugimoto</surname><given-names>Y</given-names></name><name><surname>Mochizuki</surname><given-names>H</given-names></name><name><surname>Okumichi</surname><given-names>H</given-names></name><name><surname>Takumida</surname><given-names>M</given-names></name><name><surname>Takamatsu</surname><given-names>M</given-names></name><name><surname>Kawamata</surname><given-names>S</given-names></name><name><surname>Kiuchi</surname><given-names>Y</given-names></name><article-title>Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2010</year><volume>248</volume><fpage>1601</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1007/s00417-010-1406-x</pub-id><pub-id pub-id-type="pmid">20524132</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Inatani</surname><given-names>M</given-names></name><name><surname>Takihara</surname><given-names>Y</given-names></name><name><surname>Awai-Kasaoka</surname><given-names>N</given-names></name><name><surname>Ogata-Iwao</surname><given-names>M</given-names></name><name><surname>Tanihara</surname><given-names>H</given-names></name><article-title>Prognostic risk factors for failure of trabeculectomy with mitomycin C after vitrectomy</article-title><source>Jpn J Ophthalmol</source><year>2012</year><volume>56</volume><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1007/s10384-012-0171-2</pub-id><pub-id pub-id-type="pmid">22855023</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Koleva-Georgieva</surname><given-names>DN</given-names></name><name><surname>Sivkova</surname><given-names>NP</given-names></name><name><surname>Terzieva</surname><given-names>D</given-names></name><article-title>Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy</article-title><source>Folia Med (Plovdiv)</source><year>2011</year><volume>53</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">21797106</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>DePalma</surname><given-names>RG</given-names></name><name><surname>Hayes</surname><given-names>VW</given-names></name><name><surname>Cafferata</surname><given-names>HT</given-names></name><name><surname>Mohammadpour</surname><given-names>HA</given-names></name><name><surname>Chow</surname><given-names>BK</given-names></name><name><surname>Zacharski</surname><given-names>LR</given-names></name><name><surname>Hall</surname><given-names>MR</given-names></name><article-title>Cytokine signatures in atherosclerotic claudicants</article-title><source>J Surg Res</source><year>2003</year><volume>111</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/S0022-4804(03)00075-1</pub-id><pub-id pub-id-type="pmid">12850465</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Cunliffe</surname><given-names>IA</given-names></name><name><surname>Richardson</surname><given-names>PS</given-names></name><name><surname>Rees</surname><given-names>RC</given-names></name><name><surname>Rennie</surname><given-names>IG</given-names></name><article-title>Effect of TNF, IL-1, and IL-6 on the proliferation of human Tenon&#x02019;s capsule fibroblasts in tissue culture</article-title><source>Br J Ophthalmol</source><year>1995</year><volume>79</volume><fpage>590</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1136/bjo.79.6.590</pub-id><pub-id pub-id-type="pmid">7626577</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Cvenkel</surname><given-names>B</given-names></name><name><surname>Kopitar</surname><given-names>AN</given-names></name><name><surname>Ihan</surname><given-names>A</given-names></name><article-title>Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome</article-title><source>Mediators Inflamm</source><year>2010</year><volume>2010</volume><fpage>939602</fpage><pub-id pub-id-type="pmid">20467456</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Tripathi</surname><given-names>RC</given-names></name><name><surname>Tripathi</surname><given-names>BJ</given-names></name><name><surname>Park</surname><given-names>JK</given-names></name><name><surname>Quaranta</surname><given-names>L</given-names></name><name><surname>Steinspair</surname><given-names>K</given-names></name><name><surname>Lehman</surname><given-names>E</given-names></name><name><surname>Ernest</surname><given-names>JT</given-names></name><article-title>Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures</article-title><source>Am J Ophthalmol</source><year>1991</year><volume>111</volume><fpage>247</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">1899538</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>RP</given-names></name><name><surname>Lloyd</surname><given-names>J</given-names></name><article-title>The place of sodium hyaluronate in glaucoma surgery</article-title><source>Ophthalmic Surg</source><year>1986</year><volume>17</volume><fpage>30</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">3951793</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Elgin</surname><given-names>U</given-names></name><name><surname>Berker</surname><given-names>N</given-names></name><name><surname>Batman</surname><given-names>A</given-names></name><name><surname>Simsek</surname><given-names>T</given-names></name><name><surname>Cankaya</surname><given-names>B</given-names></name><article-title>Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma</article-title><source>J Glaucoma</source><year>2006</year><volume>15</volume><fpage>466</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1097/01.ijg.0000212270.27359.64</pub-id><pub-id pub-id-type="pmid">16988612</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Good</surname><given-names>TJ</given-names></name><name><surname>Kahook</surname><given-names>MY</given-names></name><article-title>Assessment of bleb morphologic features and postoperative outcomes after Ex-PRESS drainage device implantation versus trabeculectomy</article-title><source>Am J Ophthalmol</source><year>2011</year><volume>151</volume><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.ajo.2010.09.004</pub-id><pub-id pub-id-type="pmid">21236403</pub-id></mixed-citation></ref></ref-list></back></article>